Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a conference call and webcast on Feb. 15, 2011, at 10 a.m. ET, to discuss the company’s fourth-quarter and full-year 2010 financial results.

An archive of the fourth-quarter 2010 webcast will be available at www.exactsciences.com. A replay of the conference call is available by calling 800-642-1687 domestically or 706-645-9291 internationally. The access code for the replay is 41985767. The webcast, conference call and replay are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements relating to, among other things, Exact Sciences' expectations concerning its cash resources, management’s plans, objectives and strategies and the timing of future investor conference calls. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Exact Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, Exact Sciences' ability to regain compliance with NASDAQ continued listing requirements, changes in FDA guidance or policy; the success of Exact’s strategic relationship with Genzyme; the risks of litigation; the ability to attract prospective collaborators or other parties to enter into a collaboration, acquisition or other strategic transaction with Exact; the ability to raise additional capital on acceptable terms; the success of its strategic relationship with LabCorp; Exact Sciences' ability to license certain technologies or obtain raw materials for its technologies; the ability to convince Medicare and other third-party payors to provide adequate reimbursement for Exact Sciences' technologies; the ability to increase the performance its technologies; the ability of Exact Sciences or LabCorp to lower the cost of stool-based DNA screening technologies through automating and simplifying key operational processes; and the possibility that other companies will develop and market novel or improved methods for detecting colorectal cancer. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Exact Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Exact Sciences, see the disclosure contained in Exact Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC.